# TB-500 Mechanism of Action: Actin Sequestration and the LKKTETQ Motif | TB-500

> TB-500 mechanism of action: the Ac-LKKTETQ heptapeptide carries thymosin beta-4's actin-binding motif. How the parent protein caps G-actin 1:1 — and what is established for the fragment.

The documented function of the parent protein, read like code — and a precise note on where the fragment's evidence ends.

## The TB-500 mechanism of action begins with actin

The TB-500 mechanism of action is, at root, the actin-binding chemistry of thymosin beta-4. Full-length Tβ4 is the major intracellular sequestering peptide for monomeric, globular (G-)actin: it binds a single actin monomer in a 1:1 complex and caps both of the monomer's ends, holding it out of filament assembly [1]. By buffering this pool of unpolymerized actin, the protein governs how readily the cytoskeleton remodels — which in turn sets the pace of cell migration and motility [1].

Why that one function radiates so widely is worth a sentence. Actin assembly is the engine of cell movement: a cell crawls by polymerizing actin at its leading edge. A protein that holds a reserve of monomers ready to deploy — and meters their release — sits upstream of migration, and migration is upstream of wound closure, angiogenesis and progenitor-cell recruitment. So a single biochemical job, actin-monomer buffering, plausibly connects to the broad repair phenotype the parent protein shows [9].

The structural evidence here is not a hypothesis. X-ray crystallography of a gelsolin-domain-1–Tβ4 hybrid bound to actin, resolved to 2 Å, established the 1:1 complex and the dual-end capping directly, and identified the WH2-type actin-interacting motif that underlies it [1]. WH2 — Wiskott-Aldrich syndrome protein Homology 2 — is the short actin-binding module shared by a family of monomer-sequestering and filament-assembly proteins, and the beta-thymosins are among them. Earlier biochemistry had already characterized Tβ4's interaction with muscle and platelet actin and its monomer-sequestering role in resting platelets [8].

TB-500 carries exactly this region. The `LKKTETQ` segment — residues `17-23` — is the conserved actin-binding core of the beta-thymosins, and it is the whole of the TB-500 fragment [8]. So the *structural* claim for TB-500 is well-grounded: the fragment is the binding motif. Whether the isolated motif buffers actin the way the intact protein does, at the doses used in peptide research, is the open part — a 7-mer presented on its own is not guaranteed to fold, bind and meter actin the way the same residues do inside a 43-residue context.

## What is the relationship between TB-500 and thymosin beta-4?

TB-500 is a synthetic fragment of thymosin beta-4 — residues 17-23, `Ac-LKKTETQ`, the actin-binding region of the parent. The relationship is precise: the fragment is one functional domain lifted out of a 43-residue protein. The conserved part is why the fragment is interesting; the missing 36 residues are why caution is warranted.

The practical consequence is an identity caveat that runs through the entire literature. In commerce and in the anti-doping assays, "TB-500" denotes the ~889 Da heptapeptide. But the overwhelming majority of *efficacy* studies — wound healing, cardiac repair, stroke recovery, hair-follicle activation — used full-length recombinant or synthetic Tβ4 (~4963 Da), not the 7-mer [5]. Marketing that cites those results under the name "TB-500" is borrowing the parent protein's data. The two molecules are related, but they are not interchangeable, and this site does not let one stand in for the other.

## How does TB-500 differ from full-length thymosin beta-4?

Full-length Tβ4 is a 43-residue, ~4963 Da protein; TB-500 is just its 7-residue, ~889 Da actin-binding fragment — roughly an eighth of the mass [9]. The fragment retains the actin-binding motif but not the rest of the molecule, and "the rest" is doing work: the full protein is associated with anti-inflammatory signaling, anti-fibrotic remodeling, progenitor-cell recruitment and the PINCH–ILK–Akt survival pathway, much of which is mapped to regions or activities beyond the bare LKKTETQ stretch.

The one direct bridge in the literature is encouraging but narrow: a synthetic peptide containing Tβ4's actin-binding domain reproduced aspects of the protein's wound-healing activity in db/db diabetic and aged mice [7]. That is the best evidence that the fragment carries real function. It is also a mouse wound model, not a demonstration that the 7-mer reproduces the full protein's effects in humans — a [full-length thymosin beta-4 vs the fragment](/actin-mechanism) distinction the site treats as load-bearing rather than pedantic.

## What is the amino acid sequence of TB-500 (Ac-LKKTETQ)?

TB-500 is `Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH` — `Ac-LKKTETQ` — an N-terminally acetylated heptapeptide. Reading the residues: leucine, two lysines, threonine, glutamate, threonine, glutamine. The acetyl group caps the N-terminus, and this `LKKTETQ` motif is the conserved actin-binding region shared across the beta-thymosins [8]. The formula is `C38H68N10O14` and the mass is ~889 Da. Two features are worth reading off the sequence. The pair of lysines (the two `K` residues) carry positive charge, which fits a motif that docks against actin's surface; and the N-terminal acetyl cap blocks the free amino group, a common stabilizing modification for synthetic peptides. The motif is short, conserved and well-characterized [1][8] — which is precisely why the open question is biological reach rather than chemical identity: we know exactly what TB-500 *is*; what is unsettled is what the isolated motif *does* in a human [12].

## How does TB-500 work?

TB-500 carries the LKKTETQ actin-binding motif of thymosin beta-4. In the parent protein, that motif lets Tβ4 bind a single G-actin monomer 1:1 and cap both ends, buffering the unpolymerized actin pool and regulating cytoskeletal dynamics, cell migration and motility [1]. Whether the isolated 7-mer reproduces those effects at research doses is not established in controlled human trials [12].

---

A developer-console reading of the TB-500 record — the actin-binding fragment logged against its studies, with the full-length thymosin beta-4 caveat flagged in every diff, no clinic behind the terminal and nothing here prescribed or sold.